Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Hunter Vann who wrote (3583)	6/19/1998 3:18:00 PM
From: Nemer	Respond to of 9523

Hunter: this appears to be the reason for the 4+ dollar fall biz.yahoo.com Regards ---- Nemer

To: Hunter Vann who wrote (3583)	6/19/1998 3:18:00 PM
From: Flair	Read Replies (1) \| Respond to of 9523

Hunter & all, " Pfizer Receives Non-Approvable Letter From FDA for the Antipsychotic Zeldox" Friday June 19, 2:45 pm Eastern Time NEW YORK, June 19 /PRNewswire/ -- Pfizer Inc (NYSE: PFE - news) said today it has received a non-approvable letter from the U.S. Food and Drug Administration for its novel antipsychotic Zeldox (ziprasidone Hcl). Pfizer said it is planning to meet with the FDA to discuss the issues raised by the agency, including the possible submission of additional data, as suggested by the FDA. ''We are obviously disappointed at this development, but remain confident of the safety and efficacy of Zeldox,'' said John F. Niblack, Ph.D., executive vice president of Pfizer Inc and head of Research and Development. ''We remain committed to making every effort to bring this medicine to patients in the U.S. and around the world. ''We believe that the additional studies and analyses suggested by the FDA can be undertaken in a relatively short period, and that we will be able to advance the application accordingly,'' said Dr. Niblack.